Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

A real-world study reveals that pediatric patients with IBD achieve high remission rates and cost savings using adalimumab biosimilars over time.

The Top 5 Biosimilars Articles for the Week of June 16

June 20, 2025

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

June 19, 2025

Strengthening Diabetes Care With Purpose-Built Data Infrastructure

June 18, 2025

FDA Approves Steqeyma for Children With Plaque Psoriasis, Psoriatic Arthritis

June 17, 2025

Indian Study Finds Comparable Outcomes Between Reference, Biosimilar Bevacizumab in CRC

June 7th 2025

By Deana Ferreri, PhD

Article

Real-world study reveals comparable effectiveness of bevacizumab biosimilars and Avastin in metastatic colorectal cancer (CRC), boosting clinician confidence.

The Top 5 Biosimilar Articles for the Week of June 2

June 6th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 2, 2025.

Infliximab Biosimilar Switch Due to Flare Risk: Monitoring Patients Is Crucial for Pharmacists

June 5th 2025

By Cameron Santoro

Article

Switching from reference infliximab to biosimilars (infliximab-abda and infliximab-dyyb) for rheumatic diseases may lead to treatment delays and a higher risk of disease flares, particularly when the switch is mandated by insurance.

Billions in Health Care Savings Realized Through Early Generic, Biosimilar Settlements

June 4th 2025

By Skylar Jeremias

Article

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and enhancing drug accessibility.

FDA-Approved SB16 Biosimilar Demonstrates Equivalence to Prolia

June 3rd 2025

By Skylar Jeremias

Article

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for postmenopausal osteoporosis.

Wyost and Jubbonti Launch as First Denosumab Biosimilars in the US

June 2nd 2025

By Skylar Jeremias

Article

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events.

BioRationality: The Urgency of Removing Clinical Efficacy Studies

June 2nd 2025

By Sarfaraz K. Niazi, PhD

Article

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to affordable biosimilars.

Biosimilars Regulatory Roundup: May 2025

May 31st 2025

By Skylar Jeremias

Article

FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for affordability and policy reform.

The Top 5 Biosimilar Articles for the Week of May 26

May 30th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 26, 2025.

Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships

May 29th 2025

By Skylar Jeremias

Article

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.